Below is probably one of the biggest criminals, who profited greatly jumping from FDA to Pfizer to push taxpayer funded killer drug remdesivir, taxpayer funded Pfizer COVID jab, taxpayer funded Paxlovid, etc… and a leader opposing RFK Jr. I can’t stand what Scott Gottlieb stands for and someone needs to put the spotlight on him. Of course he joined UHG!!!
As of early 2026, Dr. Scott Gottlieb, the 23rd FDA Commissioner (2017–2019), is a partner at venture capital firm New Enterprise Associates and a resident fellow at the American Enterprise Institute, focusing on health policy and technological transformation. He serves on the boards of Pfizer, UnitedHealth Group, Illumina, and Tempus, and contributes to CNBC.
Key details about Dr. Gottlieb's current work and background:
Book Release: His next book, The Miracle Century: Making Sense of the Cell Therapy Revolution, is scheduled to be published in 2026.
Corporate Board Roles: He joined the UnitedHealth Group board of directors in late 2025 and has been a director at Pfizer since 2019.
Venture Capital & Innovation: He is a special partner at NEA, where he focuses on biotechnology investments, including National Resilience and Xaira Therapeutics.
Policy & Media: He frequently comments on health policy, regulation, and pandemic preparedness, having authored the 2021 book Uncontrolled Spread.
Gottlieb is widely recognized for his work in advancing cell and gene therapy, as well as providing analysis on healthcare technology.
I wrote to him and the rest of the GSK Board in 2012, after my first book was published:
Mr Andrew Witty
Chief Executive Officer
GlaxoSmithKline Plc
980 Great West Road
Brentford, Middlesex
TW8 9GS
Date: Wednesday 15th February 2012
"Dear Mr Witty (hand written)
I’m writing to you, Bill Louv, Moncef Slaoui and A.N Other to determine who would be the most appropriate person to meet with to discuss how GSK can reduce its inventory, improve the integrity and cost of its supply chain.
The Pharmaceutical supply chain is receiving close attention from regulators and governments including the FDA who created the Office of Drug Integrity, Security and Recalls (ODSIR) and published ‘The Pathway to Global Safety and Quality’ signaling a new era of regulatory collaboration. In Europe, the Falsified Medicines Directive is demanding major changes to assure supply chain control.
PharmaFlow specializes in new thinking and education, exclusively focused on helping pharmaceutical companies make sustainable progress in transforming their supply chains. The starting point for this activity is usually a workshop with senior management aimed at raising awareness of the Supply Chain Management (SCM) transformation possibilities and lessons learnt from industries with more advanced supply chains e.g: Automotive, Semiconductors
Specifically, I would personally run the workshop covering many of the recently researched ‘best practices’ described in my newly published book, which is reviewed below.
"Hedley Rees' book is a timely antidote to the faddish advice and writing about outsourcing and lean supply chain management that has bedeviled good practice in the industry, and in supply chain management thinking in general. In a series of well researched and documented chapters about the pitfalls of inappropriate practice in the end-to-end supply chains for pharmaceuticals and drugs this volume demonstrates the key problems faced by the industry in managing supply chains holistically and for customer value. It also provides useful insights into the major positioning methodologies that the industry should use to make appropriate make/buy and strategic sourcing decisions with suppliers."
—Professor Andrew Cox, Chairman, Advisory Board, International Institute for Advanced Purchasing & Supply (IIAPS), former Director of the Centre for Business Strategy and Procurement at Birmingham University Business School, the first ever MBA in Strategic Procurement Management.
The benefits to GSK in agreeing to a management workshop on SCM, run by PharmaFlow are:
• Raised awareness of the latest SCM practices and the business improvement potential
• Improve management decision making with respect to SCM issues
• Understand the impact of strategic procurement approaches at the R & D stage, where critical SCM decisions are often taken
• Provide knowledge that could be valuable within the context of the GSK / McClaren integration
• Allow GSK management the opportunity to assess PharmaFlow’s ability to play a role in any future SCM change management programmes
Establishing an ongoing relationship with PharmaFlow will improve GSK’s ability to:
• Drive down its inventory costs
• Reduce its supply chain carbon footprint (currently 40% of total)
• Reduce supply chain risks
• Improve CSR performance
I believe it would be mutually beneficial to meet and explore the potential for PharmaFlow to work with GlaxoSmithKline in this increasingly important area.
I will call you on or before Friday 24th February to schedule a meeting and discuss any questions you have regarding the content of this letter.
Yours Sincerely
Hedley Rees
Managing Director"
Note Moncef Slaoui was copied, advisor to Donald Trump on operation warp speed!!! also, main board memeber of Moderna and Lonza.
That letter got me a meeing with Ian McCubbin, then VP, Global Supply Chain at GSK.
McCubbin is now 'Sir' Ian McCubbin, honoured for his services to the UK vaccine Task force, now Chair of UKs cell and gene therapy catapult.:
So, PT - that's a brilliant bit of detective work on Gottlieb and others - if we keep the comments coming the dots will eventually begin to join themselves up.
Great post and I will reading up on what you shared. Another area of extreme concern for the pharmaceutical industry and the practice of medicine hinge on Dennis Carlton working at DOJ in anti-trust while making hundreds of millions supporting vertical and horizontal integration for corporation. Now chief defender of the slimiest trade group PCMA. Many players, but he is one of the key players.
Of the top 3 PBMs that control formularies, pricing and access, ESI controls Magellan and Prime contractually making at least 90% of the market controlled by the Big 3 who also share executives and and hold seats as board members on PCMA. Manufacturers can only manufacture if PBMs allow it and they have expanding into manufacture with their control. They own soup to nuts and Big Pharma has been bowing to their demands or the can’t sell their drugs.
Yes, there were HMOs initially, as I understand, then PBMs claimed the market. This is US specific and patients are being screwed by the “system” - oh dear…
Thank you for reaching out. While my plate does generally have more than I can handle, I would still be interested in learning more about the “supply chain malfeasance” you mention.
I am currently traveling but perhaps we could set a time to speak during the week beginning July 22. Please send me a couple date/times that would work for you. I will be in Baltimore/Eastern Time; assuming, based on your mobile number, that you are in the UK, your late afternoon would probably work best for me.
I am a long-term big pharma whistleblower, having spent 40+ years in biopharmaceutical supply chains. I have known of your work since I covered Brook Jackson’s very short, and traumatic, time at Ventavia in early 2022 for my Inside Pharma Substack. Brook mentioned that she knew you, so I subsequently looked up the BMJ paper you wrote—excellent! Who would have thought that the world would move so little further forward over this time?
When I saw your FDA revolving doors article covered in Fierce Pharma, I had to write it up. This is the link, which is free to access:
Former FDA Commissioner Stephen Hahn joins Moderna 6-months after approving their 'vaccine'
From what I am experiencing, traction is beginning to build on exposing the supply chain malfeasance with the SARS-CoV-2 sterile @ injectables, and FDAs role in that. That is something I could help you with, if you had an interest.
No problem, of course, if you have more than enough on your plate. Alternatively, if you wished to reach out, that would be fine too.
Best regards,
Hedley
The interview never went ahead, Alison - as you might guess from his disinterest. What shocked me the most was that Brooke Jackson, someone I thought was legitimate, had no interest either 🤔🤔🤔
Disappointing😔. Maybe folks in clinical don’t understand GMP??? Trying to give benefit of the doubt. Still very odd. After following you for a couple of years one wonders if the so called freedom movement was organized in advance to give the impression justice would prevail.
Quite likely, Alison! Think I have shared this before, but here is a 2 minute animation explaining how big pharma used the discovery of penicillin to hoodwink people into believing that drugs come to market by accident, immaculately conceived by brilliant scientists with magical powers (Fauci - "follow the science").
This is the true story of peniciliin, in just over 2 minutes:
I watched the video 😊! Andrew Moyer should be famous since he figured out how to safely scale up Penicillin. Fleming figured out the first step which was significant but Moyer was responsible for safely bringing the antibiotic to market. I see what you mean, it might not be an accident this key fact has been overlooked in the discovery of Penicillin.
yes, but he wasn't interested. That is the problem we have today - they are all happier pretending they know everything and are fighting our corner...while enjoying their salaries and the attention - sorry if I'm beginning to sound somewhat bitter :O)! Thanks for your usual great comments Sandra...
See reply to Alison, Sandra. This has been a lesson in life for me - in today’s world, personal aggrandisement beats the common good every time - sadly…
Due to the prep act and EUA, NO COMPLIANCE to any standards of manufacture was required since the covid pandemic was deemed an emergency situation. In the same manner, there was NO LIABILITY attached to any process from start to finish involving the creation, manufacture and distribution of any mRNA poison substance.
The (US) government using OWS, the DOD and HHS, sanctioned the poisoning and murder of the entire population of the US. Got it? The HHS allows mRNA poisons to still be manufactured without standards and injected into the public. The prep act is enforce for another 4 years.
Are you seeing the bigger picture? Another pandemic can be declared at any time using the exact same "culture" as before...masking, distancing, lockdowns, forced injections...
Please do not use that tone in this dialogue, such as "got it!" This is not critcal thinking - it is unsubstantiated hearsay. Any more comments like this, and you will be removed as a subscriber.
Below is probably one of the biggest criminals, who profited greatly jumping from FDA to Pfizer to push taxpayer funded killer drug remdesivir, taxpayer funded Pfizer COVID jab, taxpayer funded Paxlovid, etc… and a leader opposing RFK Jr. I can’t stand what Scott Gottlieb stands for and someone needs to put the spotlight on him. Of course he joined UHG!!!
As of early 2026, Dr. Scott Gottlieb, the 23rd FDA Commissioner (2017–2019), is a partner at venture capital firm New Enterprise Associates and a resident fellow at the American Enterprise Institute, focusing on health policy and technological transformation. He serves on the boards of Pfizer, UnitedHealth Group, Illumina, and Tempus, and contributes to CNBC.
Key details about Dr. Gottlieb's current work and background:
Book Release: His next book, The Miracle Century: Making Sense of the Cell Therapy Revolution, is scheduled to be published in 2026.
Corporate Board Roles: He joined the UnitedHealth Group board of directors in late 2025 and has been a director at Pfizer since 2019.
Venture Capital & Innovation: He is a special partner at NEA, where he focuses on biotechnology investments, including National Resilience and Xaira Therapeutics.
Policy & Media: He frequently comments on health policy, regulation, and pandemic preparedness, having authored the 2021 book Uncontrolled Spread.
Gottlieb is widely recognized for his work in advancing cell and gene therapy, as well as providing analysis on healthcare technology.
Brilliant post PT!!!
Beggars belief, doesn't it, that one individual gets away with this, but he's managed it so far.
The other person to mention is Sir Andrew Witty: UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-ceo-andrew-witty-steps-down-2025-05-13/
I wrote to him and the rest of the GSK Board in 2012, after my first book was published:
Mr Andrew Witty
Chief Executive Officer
GlaxoSmithKline Plc
980 Great West Road
Brentford, Middlesex
TW8 9GS
Date: Wednesday 15th February 2012
"Dear Mr Witty (hand written)
I’m writing to you, Bill Louv, Moncef Slaoui and A.N Other to determine who would be the most appropriate person to meet with to discuss how GSK can reduce its inventory, improve the integrity and cost of its supply chain.
The Pharmaceutical supply chain is receiving close attention from regulators and governments including the FDA who created the Office of Drug Integrity, Security and Recalls (ODSIR) and published ‘The Pathway to Global Safety and Quality’ signaling a new era of regulatory collaboration. In Europe, the Falsified Medicines Directive is demanding major changes to assure supply chain control.
PharmaFlow specializes in new thinking and education, exclusively focused on helping pharmaceutical companies make sustainable progress in transforming their supply chains. The starting point for this activity is usually a workshop with senior management aimed at raising awareness of the Supply Chain Management (SCM) transformation possibilities and lessons learnt from industries with more advanced supply chains e.g: Automotive, Semiconductors
Specifically, I would personally run the workshop covering many of the recently researched ‘best practices’ described in my newly published book, which is reviewed below.
"Hedley Rees' book is a timely antidote to the faddish advice and writing about outsourcing and lean supply chain management that has bedeviled good practice in the industry, and in supply chain management thinking in general. In a series of well researched and documented chapters about the pitfalls of inappropriate practice in the end-to-end supply chains for pharmaceuticals and drugs this volume demonstrates the key problems faced by the industry in managing supply chains holistically and for customer value. It also provides useful insights into the major positioning methodologies that the industry should use to make appropriate make/buy and strategic sourcing decisions with suppliers."
—Professor Andrew Cox, Chairman, Advisory Board, International Institute for Advanced Purchasing & Supply (IIAPS), former Director of the Centre for Business Strategy and Procurement at Birmingham University Business School, the first ever MBA in Strategic Procurement Management.
The benefits to GSK in agreeing to a management workshop on SCM, run by PharmaFlow are:
• Raised awareness of the latest SCM practices and the business improvement potential
• Improve management decision making with respect to SCM issues
• Understand the impact of strategic procurement approaches at the R & D stage, where critical SCM decisions are often taken
• Provide knowledge that could be valuable within the context of the GSK / McClaren integration
• Allow GSK management the opportunity to assess PharmaFlow’s ability to play a role in any future SCM change management programmes
Establishing an ongoing relationship with PharmaFlow will improve GSK’s ability to:
• Drive down its inventory costs
• Reduce its supply chain carbon footprint (currently 40% of total)
• Reduce supply chain risks
• Improve CSR performance
I believe it would be mutually beneficial to meet and explore the potential for PharmaFlow to work with GlaxoSmithKline in this increasingly important area.
I will call you on or before Friday 24th February to schedule a meeting and discuss any questions you have regarding the content of this letter.
Yours Sincerely
Hedley Rees
Managing Director"
Note Moncef Slaoui was copied, advisor to Donald Trump on operation warp speed!!! also, main board memeber of Moderna and Lonza.
That letter got me a meeing with Ian McCubbin, then VP, Global Supply Chain at GSK.
McCubbin is now 'Sir' Ian McCubbin, honoured for his services to the UK vaccine Task force, now Chair of UKs cell and gene therapy catapult.:
https://ct.catapult.org.uk/news/press-release-cell-and-gene-therapy-catapult-appoints-ian-mccubbin-obe-cbe-as-chair-of-the-board
So, PT - that's a brilliant bit of detective work on Gottlieb and others - if we keep the comments coming the dots will eventually begin to join themselves up.
What more do you know that would be of interest?
Great post and I will reading up on what you shared. Another area of extreme concern for the pharmaceutical industry and the practice of medicine hinge on Dennis Carlton working at DOJ in anti-trust while making hundreds of millions supporting vertical and horizontal integration for corporation. Now chief defender of the slimiest trade group PCMA. Many players, but he is one of the key players.
Of the top 3 PBMs that control formularies, pricing and access, ESI controls Magellan and Prime contractually making at least 90% of the market controlled by the Big 3 who also share executives and and hold seats as board members on PCMA. Manufacturers can only manufacture if PBMs allow it and they have expanding into manufacture with their control. They own soup to nuts and Big Pharma has been bowing to their demands or the can’t sell their drugs.
Yes, there were HMOs initially, as I understand, then PBMs claimed the market. This is US specific and patients are being screwed by the “system” - oh dear…
Now there’s a thing! Great stuff Pt!
Hedley - Do you have a copy of the full interview with Doshi? It would be interesting to listen to the exchange.
This is the email exchange, Alison:
Subject: FW: Your article: Revolving doors at FDA
-----Original Message-----
From: Doshi, Peter <pdoshi@rx.umaryland.edu>
Sent: 03 July 2024 02:50
To: h.rees@pharmaflowltd.com
Subject: Re: Your article: Revolving doors at FDA
Dear Hedley,
Thank you for reaching out. While my plate does generally have more than I can handle, I would still be interested in learning more about the “supply chain malfeasance” you mention.
I am currently traveling but perhaps we could set a time to speak during the week beginning July 22. Please send me a couple date/times that would work for you. I will be in Baltimore/Eastern Time; assuming, based on your mobile number, that you are in the UK, your late afternoon would probably work best for me.
Best,
Peter
Peter Doshi
University of Maryland School of Pharmacy Email pdoshi@rx.umaryland.edu Web https://faculty.rx.umaryland.edu/pdoshi/
> On Jul 3, 2024, at 12:54 AM, h.rees@pharmaflowltd.com wrote:
“> Dear Professor Doshi,
I am a long-term big pharma whistleblower, having spent 40+ years in biopharmaceutical supply chains. I have known of your work since I covered Brook Jackson’s very short, and traumatic, time at Ventavia in early 2022 for my Inside Pharma Substack. Brook mentioned that she knew you, so I subsequently looked up the BMJ paper you wrote—excellent! Who would have thought that the world would move so little further forward over this time?
When I saw your FDA revolving doors article covered in Fierce Pharma, I had to write it up. This is the link, which is free to access:
Former FDA Commissioner Stephen Hahn joins Moderna 6-months after approving their 'vaccine'
From what I am experiencing, traction is beginning to build on exposing the supply chain malfeasance with the SARS-CoV-2 sterile @ injectables, and FDAs role in that. That is something I could help you with, if you had an interest.
No problem, of course, if you have more than enough on your plate. Alternatively, if you wished to reach out, that would be fine too.
Best regards,
Hedley
The interview never went ahead, Alison - as you might guess from his disinterest. What shocked me the most was that Brooke Jackson, someone I thought was legitimate, had no interest either 🤔🤔🤔
Disappointing😔. Maybe folks in clinical don’t understand GMP??? Trying to give benefit of the doubt. Still very odd. After following you for a couple of years one wonders if the so called freedom movement was organized in advance to give the impression justice would prevail.
Quite likely, Alison! Think I have shared this before, but here is a 2 minute animation explaining how big pharma used the discovery of penicillin to hoodwink people into believing that drugs come to market by accident, immaculately conceived by brilliant scientists with magical powers (Fauci - "follow the science").
This is the true story of peniciliin, in just over 2 minutes:
https://www.dropbox.com/scl/fi/zdseuyxcftsvcif5wz8k7/296TakingMedicinesBacktotheFuturev2-1.mp4?rlkey=pinomhdkwxxmy70boxfg545s9&dl=0
If you get a chance to watch, what does it mean to you?
I watched the video 😊! Andrew Moyer should be famous since he figured out how to safely scale up Penicillin. Fleming figured out the first step which was significant but Moyer was responsible for safely bringing the antibiotic to market. I see what you mean, it might not be an accident this key fact has been overlooked in the discovery of Penicillin.
Moyer was inducted into the U.S. Hall of Fame - 1952 I think it was. They kept that secret, down on the big Pharma ranch…
This is the clincher Robert Gaynes: https://pmc.ncbi.nlm.nih.gov/articles/PMC5403050/ check mate Patrick Vallance - give yourself up before the police get you 💪👊
So just a few conflicts of interest there lol.
you noticed!!!
Did the conversation with Peter Doshi go ahead?
yes, but he wasn't interested. That is the problem we have today - they are all happier pretending they know everything and are fighting our corner...while enjoying their salaries and the attention - sorry if I'm beginning to sound somewhat bitter :O)! Thanks for your usual great comments Sandra...
As Alison Conley says it would have been interesting to listen to, or read.
See reply to Alison, Sandra. This has been a lesson in life for me - in today’s world, personal aggrandisement beats the common good every time - sadly…
Due to the prep act and EUA, NO COMPLIANCE to any standards of manufacture was required since the covid pandemic was deemed an emergency situation. In the same manner, there was NO LIABILITY attached to any process from start to finish involving the creation, manufacture and distribution of any mRNA poison substance.
The (US) government using OWS, the DOD and HHS, sanctioned the poisoning and murder of the entire population of the US. Got it? The HHS allows mRNA poisons to still be manufactured without standards and injected into the public. The prep act is enforce for another 4 years.
Are you seeing the bigger picture? Another pandemic can be declared at any time using the exact same "culture" as before...masking, distancing, lockdowns, forced injections...
Please do not use that tone in this dialogue, such as "got it!" This is not critcal thinking - it is unsubstantiated hearsay. Any more comments like this, and you will be removed as a subscriber.